Press Releases

Annapolis, MD--The first ever International Plasma Awareness Week (IPAW) will be celebrated October 13-20. A joint initiative of the Plasma Protein Therapeutics Association (PPTA) and its member companies, IPAW is designed to: 

Mary Gustafson, PPTA Vice President, Global Regulatory Policy, was honored on July 24 with the 2013 FDA Distinguished Alumni Award at the FDA Honor Awards Ceremony, “for exceptional contributions to the regulation of blood and blood products, and as an outstanding liaison between FDA and the plasma protein industry.”

ANNAPOLIS, MD—The Plasma Protein Therapeutics Association (PPTA) opposes New Jersey Senate Bill 2132 that imposes a new tax on therapies used to treat bleeding disorders such as hemophilia.

The 2013 Plasma Protein Forum was held in Reston, Virginia on June 11-12.

The Plasma Protein Therapeutics Association (PPTA) commends the Preserving Access to Orphan Drugs Acts, bipartisan legislation that makes an important policy clarification and will remove a barrier to research and development of rare disease therapies.

The Plasma Protein Therapeutics Association (PPTA) stands together with the global primary immunodeficiency disease (PID) community to promote World PI Week, a global campaign aimed to raise awareness and improve diagnosis and treatment of PID.

April 16, 2013–The Plasma Protein Therapeutics Association (PPTA) recognizes World Hemophilia Day, an annual international event sponsored by the World Federation for Hemophilia (WFH) that seeks to raise awareness of people living with inherited bleeding disorders.

Last week, the President and Congress could not come to an agreement and on March 1, 2013 sequestration, $85 billion in across the board federal spending cuts, went into effect.

The Plasma Protein Therapeutics Association (PPTA) joins over 300 organizations in 56 countries in recognizing the 6th annual International Rare Disease Day on February 28.